Literature DB >> 22996777

[Long-term survival of a patient with giant liver metastatic breast cancer treated with trastuzumab].

Naoya Okada1, Yoshiaki Narita, Yoshihide Nanno, Mayu Shimaguchi, Kiyotaka Imamura, Rei Inoue, Toru Nakamura, Minoru Takada, Hiroaki Kato, On Suzuki, Yoshiyasu Ambo, Fumitaka Nakamura, Akihiro Kishida, Nobuichi Kashimura, Osamu Matsunami.   

Abstract

We report the long-term survival of a patient with metastatic breast cancer treated with trastuzumab and chemoendocrine therapy. The patient was a 60-year-old female. She underwent right mastectomy with axillary lymphadenectomy I c for advanced right breast cancer in 1999. In 2007, she consulted our hospital for treatment of recurrent giant liver metastasis. A giant liver metastasis up to 15 cm in diameter was detected by CT upon arrival. After 4 years of trastuzumab and chemoendocrine therapy, she was diagnosed as in progressive remission with good quality of life. Breast cancer with liver metastasis often can be life-threatening. Therefore, an optimal chemotherapy should be applied as soon as possible. Trastuzumab and chemoendocrine therapy showed efficacy for the treatment of a HER2-positive breast cancer with recurrent giant liver metastasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22996777

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

1.  Can maintenance trastuzumab be stopped in patients with HER2-positive metastatic breast cancer?

Authors:  Amy Hsieh; Ken Pittman; William K Patterson; Amanda Townsend
Journal:  BMJ Case Rep       Date:  2015-06-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.